We used a recombinant cDNA probe for human chromogranin A to measure the expression of mRNA encoded by this gene in a variety of normal human tissues and tumor specimens using Northern blot and in situ hybridization analysis. With few exceptions, the expression of chromogranin A mRNA appears to be restricted to normal tissues and tumors of neuroendocrine lineage. However, we have detected mRNA expression of this gene in 1 of 14 cell lines and 2 of 13 tumor specimens of colon adenocarcinoma. The finding of chromogranin A expression in some colon carcinomas suggests that a previously unrecognized subgroup of these tumors has neuroendocrine features. The detection of this subgroup demonstrates the potential for improving tumor classification through the use of techniques and reagents developed by recombinant DNA technology.
Introduction
Molecular genetics affords the opportunity to examine tissue specimens in a uniquely specific manner at the level of either gene structure or RNA expression. Furthermore, such evaluations do not require either an antibody or a functional assay for the protein product of the gene that is being studied. The ability to examine human tumors in this manner may both permit the subclassification of tumors into increasingly specific disease entities as well as give insight into the molecular mechanisms underlying tumorigenesis. We sought to evaluate the application of molecular analysis to tumor classification by examining various tissues for the expression of chromogranin A (cga),' a marker for tissues with neuroendocrine features. To measure cga RNA expression in normal and malignant human tissues, we used a molecular probe that recognizes the mRNA that encodes cga in Northern blot and in situ hybridization analyses.
Cga was originally isolated as the major secretory protein of adrenal medulla chromaffin granules and accounts for about one half of the soluble protein content within the granules (1) . While the precise function of cga is unknown, recent data suggest that it may play a critical role in the maturation of secretory granules (2) . In addition, the expression of this protein appears to be developmentally regulated in human chromaffin tissue with levels being first detected at 8 wk of gesta-tion and progressive increases during the first year of life (unpublished observations). Immunoreactivity of this 71 -kD acidic protein has now been extensively characterized and shown to be specifically present in normal and malignant cells of the diffuse neuroendocrine system (3) (4) (5) (6) (7) (8) . 81% of patients with neuroendocrine tumors have an elevation in serum cga levels, and serum cga is now used as a marker for neuroendocrine tumors (8) . In addition, an elevation in serum cga levels may be a useful marker for small cell lung carcinoma disease activity (9) . In this study, we have used nucleic acid hybridization analysis to characterize the expression of cga in a variety of human tissues and we have identified a number of adenocarcinomas of the colon that unexpectedly express cga.
Methods
Northern blot analysis. Total RNA was extracted from human tissues and cell lines using guanidine thiocyanate (10), and RNA concentration was determined by ultraviolet spectroscopy at 260 nm. Northern blot analysis was performed as previously described (11) . Briefly, 10-30 uig of total RNA was size fractionated on 1% agarose/formaldehyde gels. The positions of the 28S and 18S ribosomal RNA were determined by ultraviolet irradiation ofethidium bromide stained gels, and the RNA was then transferred to Nytran (Schleicher & Schuell Inc., Keene, NH). The membrane was hybridized according to the manufacturer's recommendations. To confirm that all lanes contained intact RNA at the expected concentration, the blots were stripped in 50% formamide/l X standard saline citrate (SSC) (1X SSC = 0.15 M sodium chloride/0.015 M sodium citrate) and rehybridized to an in vitro isotopically labeled actin probe (12) (data not shown).
In situ hybridization studies. In situ hybridization was performed as previously described (13, 14) with the following modifications. Cultured cells or adrenal tissue sections (8 Mum diam) were placed on polylysine-coated silanated slides, which were activated by treatment with 2.5% glutaraldehyde and 0.1 M sodium periodate (15) . After fixation with periodate-lysine-paraformaldehyde-glutaraldehyde and digestion with 0.2 N HCl and 10 Ag/ml proteinase K, samples were acetylated as previously described (16) 35S-UTP to a specific activity of I09 cpm/gg and then it was used as a molecular probe for in situ hybridization.
Results
Distribution of cga expression in normal and malignant human tissue and cell lines. To demonstrate the specificity of hybridization analysis for the characterization of cga expression in neuroendocrine cells, we examined the pattern of cga expression in human adrenal glands using in situ hybridization. As shown in Fig. 1 , a hybridization signal identifying the presence of cga mRNA is found exclusively in the neuroendocrine adrenal medulla and not in the endocrine adrenal cortex. A of this figure shows a bright field examination in which the hybridization signal appears as dark grains that are readily visible only at higher magnification (see below). B shows the identical section of adrenal gland in dark field, which demonstrates the hybridization of the cDNA probe to the central adrenal medulla while the surrounding cortex shows no hybridization. C shows a close-up bright field of the framed area from A in which the junction between the adrenal cortex and the central adrenal medulla is shown to demonstrate the specificity of hybridization to adrenal medullary cells. A Northern blot analysis of adrenal gland tissues (Fig. 2 ) confirms this pattern of reactivity, which demonstrates the presence of cga mRNA in the adrenal medulla but not in the adrenal cortex.
Northern blot analysis of tumor specimens for cga expression demonstrates the presence of the 2.1-kb chromogranin message in representative neuroendocrine tumors (Fig. 3,  lanes 3, 7, 8 , and 13) but not in carcinomas, sarcomas, and lymphoid tumors (Fig. 3, lanes 1, 2, 4-6, 9-12) . Tables I and II summarize our Northern blot evaluation of cga expression in 111 human tissues and demonstrates that expression of this gene can be detected in normal neuroendocrine tissues and neuroendocrine tumors but not in normal nonneuroendocrine tissues or most nonneuroendocrine tumors. The experiments reported in Table II indicate that the expression ofcga message in cell lines is concordant with the pattern ofexpression seen in fresh normal tissues and tumor specimens. Each human neuroendocrine tumor cell line examined expressed high levels of cga. With a single exception, tumor cell lines from sarcomas, carcinomas, lymphomas, and gliomas do not express detectable levels of this gene.
The observation of cga expression in this exception, a colon carcinoma cell line, complements the data in Table 1 , which indicates that 2 out of 13 colon adenocarcinoma tumor specimens also express cga. Fig. 4 A shows a Northern blot that demonstrates the 2.1-kb cga mRNA in a colon adenocarcinoma tumor specimen (lane 7). While the level of expression in the tumor is clearly less than the level ofexpression seen in a pheochromocytoma tumor specimen (lane 1), it is easily distinguishable from the six other colon adenocarcinomas exam- 1-3) or adrenal medulla (lanes 4-6) was hybridized to 32P-labeled pHCGA using 4 -1 8S standard Northern blotting A1.0 procedures as described in Methods. Expression of the 2.1-kb cga mRNA is readily detectable in the medullae, while no expression of this message is detectable in the cortices. We believe the differences in signal intensity between the three adrenal medullae examined here are due to contamination of the samples by varying amounts of adrenal cortical tissue that could not be completely removed from these clinical specimens before RNA extraction. ined in this experiment (lanes 2-6). The Northern blot shown in Fig. 4 B indicates that the authentic 2. 1-kb cga mRNA is readily detectable in 10 jg of total RNA derived from a colon adenocarcinoma cell line H716 (17) (lane 4), which indicates a relatively high level ofexpression in this cell line. To determine whether the cga expression in H7 16 was uniform or whether this expression was heterogeneous among the tumor cells, we examined a cytospin preparation of this cell line by in situ hybridization. Fig. 5 shows such an analysis and demonstrates that all the cells appear to be expressing cga.
Discussion
Our analysis of normal and malignant tissues for the expression ofcga RNA confirms the utility of our recombinant DNA probe pHCGA for the detection of neuroendocrine features in human tissues. The expression of cga was detected in every neuroendocrine tissue examined. With the exception of colon adenocarcinoma, nonneuroendocrine tissues did not express cga.
Using this recombinant DNA probe for cga, we have demonstrated that 2 of 13 adenocarcinomas of the colon and 1 of 14 cell lines derived from adenocarcinomas of the colon express this neuroendocrine specific gene. The colon adenocarcinomas that express cga are indistinguishable from all other 10-20 ;&g of total RNA extracted from the tissues listed in Table I was size fractionated on an agarose-formaldehyde gel, transferred to nylon membrane, and analyzed for expression of cga by hybridization to 32P-labeled pHCGA. Autoradiographs were exposed for 1-7 d with intensifying screens. Numbers in the denominator indicate total number of tissues analyzed, and numbers in the numerator indicate the number of tissues that expressed cga. Expression of cga in human tumor cell lines. 10 yg of total RNA from the human tumor cell lines listed was analyzed for expression of cga as described in Table I . Numbers are expressed as in Table I . colon adenocarcinomas by routine histopathologic criteria. Because colonic mucosa is normally populated with neuroendocrine cells, it seems reasonable that some subsets of colon adenocarcinomas might have neuroendocrine features. Indeed, carcinoid tumors of the colon are known to be of neuroendocrine origin, but these differ histologically and biologically from adenocarcinoma of the colon (18) . In addition, small cell undifferentiated carcinoma of the rectosigmoid colon is a neuroendocrine tumor occurring in less than 1% of primary rectosigmoid malignancies (19) . The colon adenocarcinomas that expressed cga had none of the light microscopic or immunohistochemical evidence of neuroendocrine differentiation that has been reported for small cell cancers of the colonic mucosa (19) . However, studies aimed at identifying more subtle evidence of neuroendocrine differentiation, such as the presence of dense core grandules or 1-dopa decarboxylase activity in the colon tumors expressing cga, will be of interest.
The colon cell line that expressed cga was derived from a patient who was presented with typical adenocarcinoma but relapsed with an anaplastic tumor from which the cell line was established. This cell line has dense core granules by electron microscopy and expressed low levels of 1-dopa decarboxylase (unpublished observations). These data, coupled with the in situ data shown in Fig. 5 , suggest that this patient relapsed with a clone oftumor cells arising from a cell that had differentiated along a neuroendocrine lineage.
We also examined the Colo 320 colon carcinoma cell line which is of disputed epithelial-neuroectodermal origin (20) . This cell line does not express cga by Northern blot analysis nor does it contain neurosecretory granules (data not shown). These data suggest that Colo 320 is not a neuroendocrine tumor cell line.
Our analysis of malignant tissues for the expression of cga RNA demonstrates the potential for the application of recombinant DNA technology to the classification of tumors. Our data define a neuroendocrine feature in a subgroup of colon adenocarcinomas that are distinguishable from carcinoid tumors of the colon and from undifferentiated small cell colon carcinomas. Our finding that some colon adenocarcinomas express cga, a very specific marker of neuroendocrine differentiation, is the first observation made using molecular techniques that suggests lineage relationships among tumors that have not been demonstrated to be related by other techniques.
Preliminary data from our laboratory indicate that both Northern blot analysis and in situ hybridization can be more sensitive than immunohistochemical analysis of gene expression (data not shown). In the specific case of cga, however, where both the mRNA and protein are expressed at high levels and an antibody is available (4), each of the techniques have specific advantages that can be exploited. For example, while immunohistochemistry can be performed more quickly than in situ hybridization, the latter technique allows a more quantitative determination of the levels of gene expression within a given cell. In this regard, the use of in situ hybridization to analyze fixed specimens of human tumors should allow determination of the precise distribution of cga expression within a given tumor specimen.
There currently exist many molecular probes for which no antibody is available, and in this situation a molecular approach to tumor classification will clearly expand the armamentarium of pathologists. Previous studies examining N-myc amplification in neuroblastoma (21) (22) (23) , neu amplification in breast carcinoma (24) , and immunoglobulin gene rearrangement in leukemia-lymphoma (25) (26) (27) (28) (29) have also suggested that the molecular genetic classification ofhuman tumors will be of clinical significance. Although more clinical studies of colonic adenocarcinomas will be required, our results suggest that the measurement of cga mRNA may prove to be a useful tool by which biologically distinct subsets of tumors that may arise during normal colonic mucosal maturation may be recognized.
